Zhan Shi

Dr. Zhan Shi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SGShan Ge
Shan Ge
YZYuwei Zhao
Yuwei Zhao
JLJun Liang
Jun Liang
ZHZhongning He
Zhongning He
KLKai Li
Kai Li
ZSZhan Shi
Zhan Shi
Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor treatment. Malignant pleural effusion (MPE) is a common end-stage manifestation of lung cancer, malignant pleural mesothelioma and other thoracic malignancies, which is invasive and often accompanied by poor prognosis, affecting the quality of life of affected patients. Currently, clinical therapy for MPE is limited to pleural puncture, pleural fixation, catheter drainage, and other palliative therapies. Immunization is a new direction for rehabilitation and treatment of MPE. The effusion caused by cancer cells establishes its own immune microenvironment during its formation. Immune cells, cytokines, signal pathways of microenvironment affect the MPE progress and prognosis of patients. The interaction between them have been proved. The relevant studies were obtained through a systematic search of PubMed database according to keywords search method. Then through screening and sorting and reading full-text, 300 literatures were screened out. Exclude irrelevant and poor quality articles, 238 literatures were cited in the references. In this study, the mechanism of immune microenvironment affecting malignant pleural effusion was discussed from the perspectives of adaptive immune cells, innate immune cells, cytokines and molecular targets. Meanwhile, this study focused on the clinical value of microenvironmental components in the immunotherapy and prognosis of malignant pleural effusion.

8 May 2024 in Phytomedicine
Verified
Journal Article
Closed access
DZDengtian Zhang
Dengtian Zhang
XTXinchen Tian
Xinchen Tian
YWYouzhi Wang
Youzhi Wang
FLFen Liu
Fen Liu
JZJiaqi Zhang
Jiaqi Zhang
SJShulong Jiang
Shulong Jiang


6 May 2026 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
ZHZhong-Ning He
Zhong-Ning He
QHQi Huang
Qi Huang
YLYi Li
Yi Li
JHJia-Qi Hu
Jia-Qi Hu
TLTong-Tong Liu
Tong-Tong Liu
宝华宝金 华
宝金 华
Background: Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. A traditional Chinese medicine (TCM) formula of Shuangshen granules (SSG) has demonstrated potential in alleviating cancer side effects and improving survival rate. Despite clinical evidence supporting its benefit, there is still insufficient understanding of the active compounds in SSG and their underlying mechanisms, which limits its broader clinical application. Methods: Lewis lung carcinoma (LLC) tumor-bearing mouse model was established to assess the efficacy of combined SSG and anti-PD-1 therapy in vivo, and myeloid-derived suppressor cells (MDSC) and CD8 + T cells were isolated for in vitro co-culture experiments, while pathological examination was conducted using hematoxylin and eosin (HE). The expression of PD-1, TIM-3, CTLA-4, LAG-3, Arg-1, IDO, iNOS, PD-L1 and Gal-9 was detected using immunohistochemistry (IHC), immunofluorescence, and flow cytometry and Western blotting. The expression of IL-2, TNF-α and IFN-γ were detected by reverse transcription-quantitative polymerase chain reaction (qPCR). Concentrations of IL-10 and TGF-β were measured by enzyme-linked immunosorbent assay (ELISA). Network pharmacology and molecular docking were utilized to screen for potential therapeutic targets and intervening signaling pathways of SSG in lung adenocarcinoma (LUAD). The predictions derived from this approach were further verified using Western blotting. Results: In vivo experiments using LLC xenograft mice demonstrated that SSG suppressed tumor growth in a dose-dependent manner, with high-dose SSG showing optimal efficacy in inhibiting tumor angiogenesis and cell proliferation. SSG enhances anti-tumor immunity by reducing T cell exhaustion and MDSC-mediated immunosuppression, with SSG + anti-PD-1 combination therapy synergistically optimizing the tumor immune microenvironment. Network pharmacology analysis revealed 5 hub targets (IL2, STAT3, HSP90AA1, LGALS3, and FGF2) associated with immune, LUAD, and active ingredients of SSG, with significant enrichment in the PI3K-Akt pathway. Compared with the control group, the protein expression levels of p-PI3K and p-Akt in the SSG group were significantly down-regulated, indicating that the PI3K-Akt pathway may be inhibited. Conclusions: SSG could dose-dependently inhibit LLC tumor growth in mice and exert antitumor effects by alleviating T-cell exhaustion and MDSC-mediated immunosuppression. Notably, IL2, STAT3, HSP90AA1, LGALS3 and FGF2, as potential targets of SSG, were significantly enriched in the PI3K-Akt pathway, which provide a novel perspective for the treatment of LUAD.

15 March 2026 in Phytomedicine
Verified
Journal Article
Closed access
SGShan Ge
Shan Ge
RQRunzhi Qi
Runzhi Qi
YZYiming Zhang
Yiming Zhang
YZYuwei Zhao
Yuwei Zhao
JWJingyang Wei
Jingyang Wei
ZSZhan Shi
Zhan Shi

1 April 2025 in Guidelines and Standards of Chinese Medicine
Verified
Journal Article
Open access
HXHaihui Xu
Haihui Xu
ZYZehui Ye
Zehui Ye
YLYiyi Lin
Yiyi Lin
RCRenbo Chen
Renbo Chen
WYWei Yang
Wei Yang
ZSZhan Shi
Zhan Shi
Objective: The washing prescription for lower limb sprains (WPFLLS) has acceptable effects on chronic ankle sprains (CAS). To provide additional evidence supporting the efficacy of the WPFLLS prescription, we designed a multicenter, double-blind, randomized controlled trial with professional ballet dancers who have a high incidence of chronic ankle sprain as the study subjects. Materials and methods: This is a multicenter, double-blind, randomized controlled trial. According to the strict inclusion and exclusion criteria, 120 ballet dancers with CAS will be selected and randomly assigned to the traditional Chinese medicine (TCM) group or to the placebo group. Patients will be treated for 14 consecutive days and followed up for 28 days. The primary outcome is the ankle-hindfoot score of the American Orthopaedic Foot & Ankle Society (AOFAS). The secondary outcomes encompass the Visual Analog Scale (VAS), the Symptom Severity and Dance Performance Quality Index, and the frequency and dosage of externally applied rescue medication. Conclusions: This trial will provide high-quality clinical evidence on the efficacy and safety of WPFLLS in the treatment of CAS and provide clinical recommendations for subsequent studies on WPFLLS.